Veru Inc. (VERU)
| Market Cap | 41.94M -28.5% |
| Revenue (ttm) | n/a |
| Net Income | -13.61M |
| EPS | -0.67 |
| Shares Out | 17.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 203,384 |
| Open | 2.420 |
| Previous Close | 2.470 |
| Day's Range | 2.410 - 2.540 |
| 52-Week Range | 2.050 - 7.330 |
| Beta | -1.20 |
| Analysts | Strong Buy |
| Price Target | 24.50 (+895.94%) |
| Earnings Date | Aug 10, 2026 |
About VERU
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly pat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for VERU stock is "Strong Buy." The 12-month stock price target is $24.5, which is an increase of 895.94% from the latest price.
News
Veru initiated with a Buy at WestPark Capital
WestPark Capital initiated coverage of Veru (VERU) with a Buy rating and $28 price target Lead asset enbosarm has completed 27 clinical trials across 1,560 subjects for various oncology indications,…
Veru Inc. Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted the clinical strategy for combining enobosarm with semaglutide to preserve muscle and improve function in older obese patients, with strong phase II data supporting efficacy and safety. Regulatory focus is on functional endpoints, and robust patent protection and a Novo Nordisk partnership position the program for strategic growth.
Veru Inc. Slides: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Veru Inc. has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Veru adavances sabizabulin following preclinical data
Veru (VERU) announced new preclinical data showing that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy in daraxonrasib resistant human pancreatic cancer cell ...
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines' RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
--New positive preclinical studies show that sabizabulin can overcome drug resistance to daraxonrasib with potent anticancer efficacy (IC50=18.2nM) in daraxonrasib resistant human pancreatic cancer ce...
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
MIAMI, FL, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...
Veru Inc. Earnings Call Transcript: Q3 2026
Enrollment completed for the phase IIb PLATEAU trial of enobosarm with interim results expected Q1 2027. Net loss narrowed year-over-year, cash position improved, and a key patent was secured, extending protection to at least 2044.
Veru Inc. Earnings release: Q3 2026
Veru Inc. released its Q3 2026 earnings on August 10, 2026, summarizing the period's financial results.
Veru Inc. Quarterly report: Q3 2026
Veru Inc. has published its Q3 2026 quarterly earnings report on August 10, 2026.
Veru reports Q3 EPS (30c) vs. (50c) last year
“We are extremely pleased with the continued enobosarm progress during this past quarter,” said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru (VERU) Inc. “We reached...
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
-- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients –
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
-- When issued U.S. patent protection until at least October 2044 -- -- Allowed patent adds to already issued enobosarm specific molecule polymorph composition of matter patents, as well as number of ...
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
MIAMI, FL, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
MIAMI, FL, July 30, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru completes enrollment in PLATEAU clinical study
Veru (VERU) announced the completion of enrollment in the Phase 2b PLATEAU clinical study to evaluate the effect of oral enobosarm 3 mg versus placebo on total body weight, fat…
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
-- Phase 2b PLATEAU clinical trial exceeds targeted full enrollment of 200 patients — -- Interim analysis results on track for calendar Q1 ‘27-- MIAMI, FL, July 27, 2026 (GLOBE NEWSWIRE) -- Veru Inc. ...
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
MIAMI, FL, July 07, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a...
Veru pact with Novo ‘significant event,’ says Canaccord
Canaccord keeps a Buy rating on Veru (VERU) with a $25 price target after the company disclosed a supply agreement with Novo Nordisk (NVO) for Wegovy. The news is a…
Veru announces clinical supply agreement with Novo Nordisk
In a regulatory filing, Veru (VERU) announced that on June 2, the company entered into a clinical supply agreement with Novo Nordisk A/S (NVO) in conjunction with the company’s Phase…
Veru price target lowered to $24 from $25 at Oppenheimer
Oppenheimer lowered the firm’s price target on Veru (VERU) to $24 from $25 to reflect the company’s Q2 results. The firm keeps an Outperform rating on the shares. Published first…
Veru Inc. Earnings Call Transcript: Q2 2026
Enobosarm showed strong phase II-B results in preserving lean mass and function in older obese patients on GLP-1 therapy, with a large market opportunity and ongoing phase II-B plateau study. Net loss narrowed and cash position improved, supporting continued R&D.
Veru Inc. Earnings release: Q2 2026
Veru Inc. released its Q2 2026 earnings on May 13, 2026, summarizing the period's financial results.
Veru Inc. Quarterly report: Q2 2026
Veru Inc. has published its Q2 2026 quarterly earnings report on May 13, 2026.
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
--Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for i nterim analysis first quarter calendar year 2027 —
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic an...